Moneycontrol Presented by Motilal Oswal
Days hours minutes
Nerolac
Presented by :

Co-Presenting Sponsor :

Capital Trade

Powered by :

Godrej Properties

Associate Sponsors :

Aegon Life
LIC Housing Finance
Indiabulls

Co-Presenting Sponsor

Capital Trade

Associate Sponsors

  • Indiabulls
  • Aegon Life
  • Image 3
Oct 12, 2017 01:20 PM IST | Source: Moneycontrol.com

Zydus receives final approval from USFDA for Desvenlafaxine extended-release tablets

Zydus Cadila has received final approval from the USFDA to market Desvenlafaxine extended-release tablets, 50 mg and 100 mg.

 
 
live
  • bselive
  • nselive
Volume
Todays L/H
More

Zydus Cadila has received final approval from the USFDA to market Desvenlafaxine extended-release tablets, 50 mg and 100 mg.

At 13:15 hrs Cadila Healthcare was quoting at Rs 497.45, up Rs 6.10, or 1.24 percent.

The share touched its 52-week high Rs 558.00 and 52-week low Rs 342.00 on 12 June, 2017 and 26 December, 2016, respectively.

Currently, it is trading 10.85 percent below its 52-week high and 45.45 percent above its 52-week low.

Market capitalisation stands at Rs 50,926.08 crore. Source : BSE
Sections
Follow us on
Available On